Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (POLF) for Resectable Locally Advanced Gastric Cancer

5 novembre 2026 mis à jour par: Zhongguang Luo, MD, Huashan Hospital

Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (POLF) for Resectable Locally Advanced Gastric Cancer : A Phase Il Study

To evaluate efficacy and safety of Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (POLF) in resectable locally advanced gastric cancer.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Description détaillée

This is a single-arm clinical study to enroll 50 patients with gastric cancer (cTNM diagnosis of cT3-4aN1-3M0). Each enrolled patient will be assigned a case number. Both this case number and the patient's initials will be entered on each page of the case report form.

Enrolled patients receive a neoadjuvant regimen of POLF in combination with sindilizumab: preoperatively, they receive a POLF regimen (paclitaxel 60 mg/m2, oxaliplatin 50 mg/m2, and 5-fluorouracil 425 mg/m2) administered once weekly for a total of 6 doses, and in combination with sindilizumab 200 mg intravenously once every 3 weeks for a total of 2 doses. Upon completion of the evaluation, patients whose tumors were judged to be resectable underwent radical surgery and received six postoperative doses of the POLF regimen and two doses of Sindilizumab as adjuvant therapy.

Postoperative imaging evaluations will be performed every three months until disease recurrence. Survival follow-up was performed every three months after disease recurrence. Patients will receive neoadjuvant therapy for 6 weeks preoperatively and adjuvant therapy for 6 weeks postoperatively unless intolerable toxicity occurs, the patient refuses to continue treatment, or treatment is delayed beyond 3 weeks. Patients will be under study observation during treatment and 30 days after treatment termination, and will receive long-term follow-up for 5 years postoperatively. Ultimately, pCR and MPR will be the primary study endpoints, and ORR, DCR, 2-year PFS rate, 3-year OS rate and safety will be the secondary study endpoints to evaluate the efficacy and safety of the neoadjuvant regimen of POLF combined with sindilizumab, as well as to explore the immune activation effect and mechanism of the regimen using peripheral blood and tumor tissue samples.

Type d'étude

Interventionnel

Inscription (Estimé)

50

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Shanghai, Chine
        • Recrutement
        • Huashan Hospital, Fudan University
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Signed written Informed Consent Form

  2. Male or female, age ≥ 18 years old

  3. Histologically confirmed gastric adenocarcinoma, diagnosed as locally progressive according to the AJCC 8th ed, cTNM diagnosis of cT3-4aN1-3M0 and resectable lesion as assessed by the investigator

  4. No prior systemic therapy such as surgery, radiotherapy, or immunotherapy for the disease at hand

  5. Consent to radical surgical treatment and no contraindications to surgery as determined by the surgeon

  6. ECOG PS: 0-1 score

  7. Expected survival > 6 months

  8. Adequate organ function, must meet the following laboratory specifications:

    8.1 Absolute neutrophil count (ANC) ≥ 1.0x10^9/L; 8.2 Platelets ≥ 80x10^9/L; 8.3 Hemoglobin > 7g/dL; 8.4 Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (Total bilirubin > 1.5 x ULN but direct bilirubin ≤ ULN are allowed to be enrolled); 8.5 AST, ALT ≤ 2.5×ULN; 8.6 Blood creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 60 ml/min; 8.7 INR or PT ≤ 1.5 times ULN; 8.8 TSH within normal range (Enrollment allowed if baseline TSH is outside normal range but FT4 is within normal range); 8.9 Myocardial enzyme profile within normal range;

  9. Negative pregnancy test in women of childbearing age

  10. Need to use contraception with an annual failure rate of less than 1% if there is a risk of conception

Exclusion Criteria:

  1. Endoscopically show signs of active bleeding from the lesion
  2. Current participation in an interventional clinical study or treatment with another investigational drug or use of an investigational device within 4 weeks prior to the first dose of study drug
  3. Prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or agents targeting CTLA-4, OX-40, CD137, etc.
  4. Diagnosis of a malignant disease other than gastric cancer within 5 years prior to the first dose of therapy
  5. Active autoimmune disease requiring systemic therapy within 2 years prior to the first dose of the drug
  6. Live vaccination within 30 days prior to the first administration of the drug
  7. Have received systemic systemic therapy with proprietary Chinese medicines with antitumor indications or immunomodulatory drugs within 2 weeks prior to the first administration of the drug
  8. Have received systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of treatment
  9. Has not fully recovered from any intervention-induced toxicity and/or complications (excluding malaise or alopecia) prior to initiation of therapy
  10. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation
  11. Known hypersensitivity to drugs used in this study
  12. Known history of HIV infection
  13. Untreated active hepatitis B
  14. Active HCV infection
  15. Pregnant or lactating women
  16. The presence of any serious or uncontrolled systemic disease
  17. Other factors that, in the judgment of the investigator, may affect the outcome of the study

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: sintilimab+metronomic POLF

Sintilimab therapy(200mg, iv,d1,Q3W, 2cycles)and POLF chemotherapy (Paclitaxel 60 mg/m2, oxaliplatin 50 mg/m2, 5-fluorouracil 425mg/m2, d1, QW, 6cycles) followed by adjuvant sintilimab therapy(200mg, iv,d1,Q3W, 2cycles)and POLF chemotherapy (Paclitaxel 60 mg/m2, oxaliplatin 50 mg/m2, 5-fluorouracil 425mg/m2, d1, QW, 6cycles) neoadjuvant chemotherapy (8 weeks) preceding surgery (3 weeks after completion of chemotherapy) followed by adjuvant chemotherapy (16 weeks, begin within 12 weeks after surgery)

Drug: Sintilimab 200mg iv d1 Q3W, 2cycles

Drug: Paclitaxel 60 mg/m2, d1, QW,6cycles

Drug: Oxaliplatin 50 mg/m2, d1, QW, 6cycles

Drug: 5-fluorouracil 425mg/m2 ,d1 ,QW, 6cycles

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percentage of participants with no residual surviving tumor cells in resection specimens and lymph nodes
Délai: up to 6 weeks after first dosing

Pathological complete response rate (pCR), defined as the proportion of participants with no residual viable tumor cells on microscopy and negative lymph nodes as a percentage of all participants. We will evaluate pathological complete response rate of primary tumor and locally metastatic lymph nodes after 6 weeks of neoadjuvant therapy.

up to 6 weeks after first dosing
Percentage of participants with ≤10% tumor cell survival in resection specimens
Délai: up to 6 weeks after first dosing

Major pathologic response (MPR) rate, defined as the proportion of participants with ≤10% surviving tumor cells in the resection specimen as a percentage of all participants. We will evaluate major pathological response rate of primary tumor and locally metastatic lymph nodes after 6 weeks of neoadjuvant therapy.

up to 6 weeks after first dosing

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Percentage of participants achieving complete remission (CR) and partial remission (PR) after treatment
Délai: 2 to 6weeks after the end of treatment

Objective remission rate (ORR), the percentage of participants whose tumors shrink by a certain amount and remain there for a certain period of time, including complete remission (CR) and partial remission (PR). CR (Complete remission): Complete disappearance of the target lesion, with no new lesions produced, and lasting for more than 4 weeks. PR (Partial remission): the sum of the largest diameters of the target lesions is reduced by more than 30%, and lasts for more than 4 weeks.

2 to 6weeks after the end of treatment
Percentage of participants achieving remission (PR+CR) and lesion stabilization (SD) after treatment
Délai: 2 to 6weeks after the end of treatment

Disease control rate (DCR) is the percentage of participants who achieve remission (PR+CR) and stabilization of lesions (SD) after the treatment. Stable disease (SD) means that the sum of the largest diameters of the tumor lesions has not shrunk to PR, or has not enlarged to PD.

2 to 6weeks after the end of treatment
2-year progression-free survival (PFS) rate
Délai: From enrollment to study completion, assessed up to 2 years

Percentage of participants who survived or were free of tumor progression from enrollment to the second year of follow-up.

From enrollment to study completion, assessed up to 2 years
3-year overall-survival (OS) rate
Délai: From enrollment to study completion, assessed up to 3 years

Percentage of participants who survived from enrollment to the third year of follow-up.

From enrollment to study completion, assessed up to 3 years
Number of participants with treatment-related adverse events as assessed by NCI-CTC
Délai: From enrollment to study completion, assessed up to 3 years

Toxicity deaths and early withdrawal from treatment due to toxic effects will be described. Toxicity assessment of adverse events and serious adverse events (SAEs) using the NCI-CTC.

From enrollment to study completion, assessed up to 3 years

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Number of immune cells in peripheral blood
Délai: From enrollment to study completion, assessed up to 3 years

Peripheral blood will be analyzed for the number of immune cells after applying flow cytometry and mRNA sequencing.

From enrollment to study completion, assessed up to 3 years
Proportion of immune cells in peripheral blood
Délai: From enrollment to study completion, assessed up to 3 years

Peripheral blood will be analyzed for the proportion of immune cells after applying flow cytometry and mRNA sequencing.

From enrollment to study completion, assessed up to 3 years
Number of immune cells in tumor tissues
Délai: From enrollment to study completion, assessed up to 3 years

Apply mRNA sequencing, immunohistochemistry and immunofluorescence to analyze the number of immune cells in tumor tissues, including CTL, Treg, DC, TAM, MDSC, NK, NKT and so on.

From enrollment to study completion, assessed up to 3 years
Distribution of immune cells in tumor tissue
Délai: From enrollment to study completion, assessed up to 3 years

Apply mRNA sequencing, immunohistochemistry and immunofluorescence to analyze the distribution of immune cells in tumor tissues, including CTL, Treg, DC, TAM, MDSC, NK, NKT and so on.

From enrollment to study completion, assessed up to 3 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

18 octobre 2023

Achèvement primaire (Estimé)

30 décembre 2026

Achèvement de l'étude (Estimé)

31 décembre 2026

Dates d'inscription aux études

Première soumission

12 septembre 2023

Première soumission répondant aux critères de contrôle qualité

22 septembre 2023

Première publication (Réel)

26 septembre 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner